Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis T.W.V. Daniels, G.B. Rogers, F.A. Stressmann, C.J.

Slides:

Advertisements

Similar presentations

Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.

Advertisements

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis Annemarie Lee,

Dietary supplementation with multiple micronutrients: No beneficial effects in pediatric cystic fibrosis patients Johanna H. Oudshoorn, Peter H.C. Klijn,

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis,

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

William G. Flight, Jonathan Shaw, Susan Johnson, A

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

Scott D. Sagel, Marci K. Sontag, Meg M

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

The ease of breathing test tracks clinical changes in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Pulmonary exacerbations in CF patients with early lung disease

The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited Abaigeal D. Jackson, Leslie Daly,

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples G.B. Rogers, P. Marsh, A.F. Stressmann, C.E. Allen,

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Pulmonary nocardiosis in cystic fibrosis

Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis Marthe S. Paats, Ingrid M. Bergen, Marleen Bakker,

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Valerie Waters, Eshetu G

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Voriconazole therapy in children with cystic fibrosis

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Treatment intensity and characteristics of MRSA infection in CF

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Does the timing of inhaled dornase alfa matter?

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis T.W.V. Daniels, G.B. Rogers, F.A. Stressmann, C.J. van der Gast, K.D. Bruce, G.R. Jones, G.J. Connett, J.P. Legg, M.P. Carroll Journal of Cystic Fibrosis Volume 12, Issue 1, Pages 22-28 (January 2013) DOI: 10.1016/j.jcf.2012.05.008 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 The (A) relative change in forced expiratory volume in the first second (FEV1), and (B) summed VAS scores, before during and following initiation of treatment for cystic fibrosis pulmonary exacerbation (CFPE) in twelve subjects. Error bars represent 95% confidence interval around the median. Journal of Cystic Fibrosis 2013 12, 22-28DOI: (10.1016/j.jcf.2012.05.008) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 The (A) mean relative abundance (%) of Pseudomonas aeruginosa and (B) mean bacterial taxa richness (excluding P. aeruginosa) over the time series. Open circles denote pre-IV treatment and closed circles denote during/post IV treatment. Error bars represent the standard deviation of the mean (n=12). Journal of Cystic Fibrosis 2013 12, 22-28DOI: (10.1016/j.jcf.2012.05.008) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 The (A) mean relative abundance (%) of Pseudomonas aeruginosa and (B) mean bacterial taxa richness (excluding P. aeruginosa) pre- and during IV treatment. Error bars represent the standard deviation of the mean (n=36). Journal of Cystic Fibrosis 2013 12, 22-28DOI: (10.1016/j.jcf.2012.05.008) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions